Eli Lilly, Pfizer, Moderna... Pharma is Embracing AI Trend
ALSO: A New AI Chatbot for Biotech Investors; This Company Is Building AI Infrastructure for Life Sciences
Welcome to BiopharmaTrend’s newsletter, ‘Where Tech Meets Bio,’ where we talk about technologies, breakthroughs, and great companies moving the biopharma industry forward.
If you've received it, then you either subscribed or someone forwarded it to you. If the latter is the case, subscribe by pressing this button:
Now, let’s get to this week’s topic!
Leading Pharma Companies Embrace AI Trend
Whether you think AI is hype or hope in the pharma space, leading pharma companies seem to firmly embrace the trend.
Eli Lilly has just appointed its first Chief AI Officer, Thomas Fuchs, who will lead AI initiatives across drug discovery, clinical trials, manufacturing, and commercial operations.
Fuchs, previously at Mount Sinai and founder of Paige, brings deep expertise in AI applications for healthcare.
This follows similar moves by other major players like Pfizer, Merck KGaA, and GSK, as the industry continues to integrate AI leadership roles into their executive teams.
Earlier this year, Pfizer appointed Berta Rodriguez-Hervas as its Chief AI and Analytics Officer. Rodriguez-Hervas, with a background at Nvidia and Tesla, is responsible for leading AI-driven initiatives across the company’s drug discovery, clinical trials, and analytics functions.
Moderna has enterprise-wide programs with LLMs. Since early 2023, Moderna has implemented ChatGPT Enterprise, including a customized internal AI system called mChat, which according to the company has already seen over 80% adoption among employees.
This partnership aims to also enhance Moderna's R&D, legal, manufacturing, and commercial operations, and includes tools like Dose ID, which assists in optimizing vaccine dose selection by using AI-driven analytics and reporting.
These are just a couple of examples, but really, I think pretty much every large pharma company is doing it at this point.
Results?
Let's see how it goes. I think gen AI is useful for many operational and research tasks where results could be an approximation and not a 100% accurate thing (and there are many of those types of work at a company).
Also, (perhaps we all forgot about it by now!) but gen AI is NOT THE ONLY AI out there! For instance, I think (and totally agree with Gary Marcus on this) that the future is neurosymbolic. But let's spare this for the next post…
A New AI Chatbot for Biotech Investors
A novel LLM-supported online service for biotech investors. If public markets is your thing, it could be really useful!